

QuantaFlo[®] PAD

Supporting the
"Prevention of Amputation in Veterans Everywhere."



'PAVE' the Way to Early Detection of Vascular Disease

"Veterans Administration strives to provide care in order to prevent and treat lower extremity complications that can lead to amputation, and to restore function, thereby improving quality of life for Veterans who have already undergone an amputation."

- Veterans Administration¹



~25%
of the Veteran population was affected by diabetes²



80%
of Veterans with amputations also had diabetes³



46.5%
of Veterans with diabetes also had PAD⁴



~67%
of patients with PAD had a detectable pulse⁵




1 Year
Prior to Lower Extremity Amputation:

- 49.9% had no outpatient vascular surgeon clinic visit
- 30.1% Veterans had no vascular assessment⁶

VASCULAR DISEASE TESTING IN PRIMARY CARE IS PRACTICAL AND COST-EFFECTIVE.

- The QuantaFlo PAD test delivers fast and accurate results in less than 3-minutes
- Medical intervention at the point-of-care may offer a greater opportunity to lower costs and improve patient care
- Convenient and easy to use, the QuantaFlo PAD device is portable and allows testing at the location that is most comfortable for the patient
- QuantaFlo PAD accuracy and sensitivity has shown to be higher than cuff-based ABI when evaluated by Duplex ultrasound or angiography⁷
- QuantaFlo PAD is successfully used in primary care offices, specialty practices, health fairs, home assessments and other healthcare delivery settings

QuantaFlo® PAD*, an application that supports the provider in the **early detection** (borderline/mild) of **Peripheral Arterial Disease (PAD)**.



2 quick and easy steps to an accurate QuantaFlo PAD test results




1. Prepare



2. Perform



Read Report



- ✓ FDA Cleared
- ✓ Quick, Easy and Pain Free
- ✓ Ability to detect PAD in non-compressible, calcified arteries
- ✓ No associated risk as with traditional cuff-based ABI
- ✓ Can be performed by ancillary staff
- ✓ Point of Care - actionable report in less than 3-minutes - to guide provider in next steps

1. Veterans Health Administration. (2017). Prevention of amputation in veterans everywhere (PAVE) program. <https://www.navao.org/wp-content/uploads/2017/04/VHA-Directive-1410-Prevention-of-Amputation-in-Veterans-Everywhere-PAVE-Program-3-31-17.pdf>
2. Office of Research and Development. VA research on diabetes. <https://www.research.va.gov/topics/diabetes.cfm>
3. Department of Veteran Affairs & Department of Defense. (2017). VA/DoD clinical practice guideline for rehabilitation of individuals with lower limb amputation. <https://www.healthquality.va.gov/guidelines/Rehab/amp/VADoDLLACPG092817.pdf>
4. Willey, J., Mentias, A., Vaughn-Sarrazin, M., McCoy, K., Rosenthal, G., & Girotra, S. (2018) Epidemiology of lower extremity peripheral artery disease in veterans. *Journal of Vascular Surgery*, 68(2), 527-535. e5. <https://doi.org/10.1016/j.jvs.2017.11.083>
5. Collins, T.C., Suarez-Almazor, M., & Peterson, N.J. (2006) An absent pulse is not sensitive for the early detection of PAD. *Journal of Family Medicine*, 38(1), 38-42. <https://pubmed.ncbi.nlm.nih.gov/16378257/>
6. Alabi, O., Berival, S., & Gallini, J.W. (2023). Association of health care utilization and access to care with vascular assessment before major lower extremity amputation among US veterans. *JAMA Surgery*, 158(6), e230479. <https://doi.org/10.1001/jamasurg.2023.0479>
7. Schaefer, M.E., Long, J.B., & Pollick, C. (March, 2016). Non-invasive detection of vascular disease in the arteries of the lower extremity: Clinical evaluation of QuantaFlo compared to doppler and definitive imaging. Supplement to *Cath Lab Digest*.

* QuantaFlo is the product, 'PAD' is the module within the product.



Contract Holder
Contract # 36F79723D0166